GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SHSE:600329) » Definitions » Cash And Cash Equivalents

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Cash And Cash Equivalents : ¥2,458 Mil (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group Cash And Cash Equivalents?

Tianjin Pharmaceutical Da Ren Tang Group's quarterly cash and cash equivalents increased from Sep. 2023 (¥2,019.89 Mil) to Dec. 2023 (¥2,125.20 Mil) and increased from Dec. 2023 (¥2,125.20 Mil) to Mar. 2024 (¥2,457.62 Mil).

Tianjin Pharmaceutical Da Ren Tang Group's annual cash and cash equivalents increased from Dec. 2021 (¥2,283.18 Mil) to Dec. 2022 (¥2,882.52 Mil) but then declined from Dec. 2022 (¥2,882.52 Mil) to Dec. 2023 (¥2,125.20 Mil).


Tianjin Pharmaceutical Da Ren Tang Group Cash And Cash Equivalents Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group Cash And Cash Equivalents Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,479.44 1,987.33 2,283.18 2,882.52 2,125.20

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,455.31 2,103.96 2,019.89 2,125.20 2,457.62

Tianjin Pharmaceutical Da Ren Tang Group Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Tianjin Pharmaceutical Da Ren Tang Group  (SHSE:600329) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Tianjin Pharmaceutical Da Ren Tang Group Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Business Description

Traded in Other Exchanges
Address
No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Headlines

No Headlines